IAPO4Rec'd PCT 24 JUL 2008

CASE 51752-US-PCT

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV971833625US

Date of Der

Express Mail Label Number

.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

ABIA CREASEY

INTERNATIONAL APPLICATION NO: PCT/US2005/009097

FILED: 17 MARCH 2005

U.S. APPLICATION NO: 10/593,135

35 USC §371 DATE: 18 SEPTEMBER 2006

FOR: TREATMENT OF SEVERE COMMUNITY-ACQUIRED PNEUMONIA

BY ADMINISTRATION OF TISSUE FACTOR PATHWAY INHIBITOR

(TFPI)

MS: PCT

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-9308

Encl.: 1449 forms (16 pages)

168 References

Date: 7/24/2008

Respectfully submitted,

L'eslie Fischei

Attorney for Applicant

Reg. No. 58,393